Your browser doesn't support javascript.
loading
Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification.
Liu, L; Toung, J M; Jassowicz, A F; Vijayaraghavan, R; Kang, H; Zhang, R; Kruglyak, K M; Huang, H J; Hinoue, T; Shen, H; Salathia, N S; Hong, D S; Naing, A; Subbiah, V; Piha-Paul, S A; Bibikova, M; Granger, G; Barnes, B; Shen, R; Gutekunst, K; Fu, S; Tsimberidou, A M; Lu, C; Eng, C; Moulder, S L; Kopetz, E S; Amaria, R N; Meric-Bernstam, F; Laird, P W; Fan, J-B; Janku, F.
Afiliação
  • Liu L; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: lliu3@illumina.com.
  • Toung JM; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Jassowicz AF; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Vijayaraghavan R; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Kang H; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Zhang R; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Kruglyak KM; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Huang HJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Hinoue T; Van Andel Research Institute, Grand Rapids, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Shen H; Van Andel Research Institute, Grand Rapids, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Salathia NS; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Bibikova M; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Granger G; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Barnes B; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Shen R; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Gutekunst K; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Fu S; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Tsimberidou AM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Lu C; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Eng C; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Moulder SL; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Kopetz ES; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Amaria RN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Laird PW; Van Andel Research Institute, Grand Rapids, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Fan JB; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: fjanku@mdanderson.org.
Ann Oncol ; 29(6): 1445-1453, 2018 06 01.
Article em En | MEDLINE | ID: mdl-29635542
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: DNA de Neoplasias / Biomarcadores Tumorais / Metilação de DNA / Ácidos Nucleicos Livres / Neoplasias Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: DNA de Neoplasias / Biomarcadores Tumorais / Metilação de DNA / Ácidos Nucleicos Livres / Neoplasias Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article